Recruiting

Testing a new medication to protect kidneys in type 1 diabetes

Plain-English translation of NCT05822609 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether , a medication that's already used for other conditions, can help protect your kidneys if you have type 1 diabetes and early kidney disease. The study will compare the medication to a placebo (a dummy pill with no active ingredient) over 26 weeks to see if it improves kidney health and reduces harmful protein in your urine. Researchers will also monitor your blood sugar control and overall safety.

Type 1 diabetes can damage your kidneys over time, and current treatments don't fully stop this damage. This trial is exploring whether this medication might offer additional kidney protection beyond what existing treatments provide.

Do you qualify?

You likely qualify if…

you are at least 18 years old and have had type 1 diabetes for 5 or more years
you have persistent kidney changes shown by protein in your urine (measured as albumin-to-creatinine ratio ≥30 mg/g on two recent tests)
your kidney function is still at a safe level to participate (estimated glomerular filtration rate ≥20)
you are taking stable doses of blood pressure and cholesterol medications and are willing to keep them steady throughout the trial
if you can have children, you are using reliable birth control during the study

You likely don't qualify if…

your recent blood sugar control has been very poor (HbA1c >9%) or you have had serious diabetes complications like diabetic ketoacidosis in the past month
you are currently taking other medications for diabetes that aren't approved for type 1 diabetes, such as metformin, GLP-1 drugs, or SGLT-2 inhibitors
you have a personal or family history of medullary thyroid cancer or a thyroid nodule
you have experienced more than 2 severe low blood sugar episodes in the past 6 months or frequent lows during the study run-in period
you are pregnant, nursing, planning to become pregnant, or have uncontrolled high blood pressure or thyroid disease

What participation looks like

You will visit the research center for screening and baseline tests, including kidney function tests and continuous glucose monitoring to measure your blood sugar patterns. Over 26 weeks, you'll gradually increase the dose of either the medication or placebo (you won't know which), reaching the highest dose by week 12 and then continuing for another 14 weeks. You'll have follow-up visits to monitor your kidney function, protein in your urine, blood sugar control, and any side effects, with researchers adjusting your insulin doses as needed to keep your blood sugar stable.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(4 sites)

United States

University of Colorado Anschutz Medical Campus, Aurora, Colorado

University of Washington, Seattle, Washington

Providence Sacred Heart Medical Center, Spokane, Washington

Canada

Toronto General Hospital, University Health Network, Toronto, Ontario